poster
Brilaroxazine (BXZ, RP5063) is an investigational drug in development by Reviva Pharmaceuticals for neuropsychiatric & inflammatory disorders. It is a serotonin-dopamine modulator displaying partial agonist activity at D2/3/4 & 5-HT1A/2A receptors & antagonist activity at 5 HT2B/7 receptors with binding affinity for 5-HT2B > D2.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.